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ABSTRACT 
Purpose: Keratoconus (KC) is a disease characterized by thinning and deformation of 
the cornea, but its etiology remains unknown. Seventy percent of the corneal stroma 
consists of collagen, which is composed of three intertwined polypeptide chains with 
glycine-hydroxyproline-proline repeats along their sequence. Arginase is a 
cytoplasmatic enzyme and catalyzes the conversion of arginine to urea and ornithine, 
which serves as a precursor for the endogenous synthesis of proline and 
hydroxyproline. The purpose of this study was to analyze arginase activity, as well as 
collagen and urea formation in normal and KC-keratocytes and to determine the 
impact of urea on keratocyte viability and proliferation, in vitro. 
Methods: Primary human keratocytes were isolated by digestion in collagenase (1.0 
mg/ml) from surgically removed corneas of 8 keratoconus patients and 8 normal 
human corneal buttons, and cultured in DMEM/Ham's F12 medium supplemented 
with 10% fetal calf serum. Arginase activity and urea concentration were measured in 
cell-lysates, hydroxyproline concentration in supernatant of cultured keratocytes using 
colorimetric assay. Cell viability and cell proliferation of cultured keratocytes were 
assessed after treatment with urea at concentrations up to10 mM for 24 h using assays 
for metabolic activity and DNA replication.  
Results: Arginase activity and urea concentration in KC-keratocytes decreased by 
about 50 % compared to normal keratocytes (p=0.003 and p=0.008). Hydroxyproline 
synthesized by cultured KC-keratocytes was also approximately 50 % less compared 
to normal keratocytes (p=0.02) and this difference decreased following treatment with 
5.0 or 10.0 mM urea (p= 0.02; 0.03), without any change in cell viability (p>0.09). 
However, the urea treatment increased modestly (by 20 %) the proliferation rate of 
KC-keratocytes (p= 0.04; 0.04; 0.04), without any effect on normal cultured 
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keratocytes (p>0.09). 
Conclusions: We identified suppressed arginase activity in the metabolic program of 
cultured keratoconus keratocytes. The level of urea, as one product of the enzyme 
arginase was also decreased. This results in impaired collagen synthesis, evidenced in 
the culture by reduced hydroxyproline synthesis. In addition, our data showed that the 
other product of the arginase reaction, urea supports the proliferation of 
KC-keratocytes, without changes in their viability. The metabolic reprogramming of 
keratoconus keratocytes and its impact on development of a clinically detectable 
keratoconus disease has to be further analyzed.  
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INTRODUCTION 
Keratoconus (KC) is a disease characterized by thinning and deformation of the 
cornea. Patients develop first symptoms usually in early teens to early twenties with 
an incidence of about 1/2,000 [1]. Keratoconus starts usually during puberty with 
progression until the third decade of life [2]. The etiology of keratoconus remains 
unknown, but some researchers suggest involvement of inflammatory enzymes beside 
genetical components [3–5]. Different proteases like matrix-metalloproteinase-1 
(MMP-1) [6], MMP-9 and MMP-13 [7] may be involved in keratoconus disease. 
Thinning of a keratoconus cornea occurs with degradation of the extracellular matrix. 
Seventy percent of the corneal stroma consists of collagen, predominantly of type I 
collagen (80-90 %) and of collagen V [8, 9]. The fibril-forming collagens are 
composed of triple helical subunits, the stability of which is based on the repeating 
glycine-X-Y amino acid triplets in the structure of the intertwined polypeptide chains 
(38 % of position X in these repeats is occupied by hydroxyproline and 28 % of 
position Y by proline) [10] . Hydroxyproline is formed by a posttranslational 
hydroxylation of proline in protocollagen and thus its quantity depends on the rate of 
collagen synthesis.  
Arginase is an essential enzyme in tissue regeneration, cell proliferation and 
anti-inflammation [11]. Arginase, as a cytoplasmic enzyme catalyzes the conversion 
of arginine to urea and ornithine. Ornithine will be further converted by ornithine 
aminotransferase and pyrroline-5-carboxylate reductase to proline, which is 
incorporated in protocollagen, the precursor of collagen and some of these proline 
residues are further transformed to hydroxyproline (Figure 1). Therefore, arginase 
may play an essential role in collagen production of the cells, also in keratoconus 
patients.  
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Interestingly, in a previous study, we detected decreased urea concentration in 
aqueous humour of keratoconus patients, compared to controls [12]. In addition, Jäger 
et al. have shown that urea concentration in tear film of dry eye subjects is decreased 
compared to healthy controls [13]. Keratoconus is often associated with dry-eye 
syndrome (DES), which results in symptoms of discomfort, tear film instability 
caused by increased osmolarity of the tear film [14].  
These findings raise the hypothesis that changes related to urea metabolism may be 
part of the keratoconus disease phenotype. In view of the known disturbances of 
collagen turnover in keratoconus patients, the current study was undertaken in attempt 
to address the possibility that impaired arginase-dependent supply of proline could 
result in impaired collagen synthesis and thus contribute to the pathomechanism of 
keratoconus disease.  
Therefore, in the current study, our purpose was to analyze arginase activity, as well 
as urea concentration and hydroxyproline synthesis of normal and keratoconus 
keratocytes and to define the impact of urea on keratocyte viability and proliferation.  
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MATERIALS AND METHODS 
Materials 
Dulbecco's Modified Eagle Medium: (Nutrient Mixture F-12 (DMEM/F12)); fetal calf 
serum (10%); P/S (1% of 10000 u penicillin/ 10 mg streptomycin per ml); 0.05% 
trypsin/ 0.02% ethylenediaminetetra-acetic acid (EDTA), PBS, CelLytic™, Urea 
assay kit and Arginase activity assay kit were purchased from Sigma-Aldrich® GmbH 
(Deisenheim, Germany), alamarBlue® from Invitrogen (Karlsruhe, Germany). 
Collagenase A, Dispase II and BrdU Proliferation-ELISA were obtained from Roche 
Diagnostics (Mannheim, Germany). Colorimetric assay for Hydroxyproline was 
purchased from Chondrex. Inc. (Redmond, USA). 
 
Isolation of primary human corneal keratocytes  
Eight human normal corneas were obtained from the Saarland University Medical 
Center Eye Bank and 8 corneas from keratoconus patients from elective penetrating 
keratoplasties. To isolate keratocytes, the human corneoscleral buttons were 
aseptically rinsed in phosphate-buffered saline (PBS) before removal of the 
endothelium including Descemet’s membrane by sterile surgical disposable scalpel. A 
central corneal button with epithelium was cut using a 8.0 mm hand-held trephine and 
thereafter incubated in culture medium containing 2.4 U/ml Dispase II for 4 hours at 
37 °C. Thereafter, the corneal button was washed with PBS for several times and the 
already loose corneal epithelium was removed with surgical disposable scalpel. The 
remaining corneal stroma was incubated in culture medium with 1.0 mg/ml 
collagenase A for 8-10 hours at 37 °C. The digested tissue and cells were pipetted 
three times and centrifuged at 800 g for 7 minutes and finally resuspended in 1.0 ml 
culture medium, which consisted of basic medium (DMEM/F12) supplemented with 
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10% FCS and 1% P/S. The cell suspension was seeded in 6-well plates and the 
medium was changed 24 hours after seeding. Medium was changed every 2 to 3 days 
until keratocytes reached confluence. The cells were subcultured in 25 cm2 culture 
flasks after 5 to 10 days following dispersal with 0.05% trypsin/ 0.02% 
ethylenediaminetetra-acetic acid (EDTA) for 3 to 5 minutes and the passage 4 to 8 of 
cells was used for experiments. Normal keratocyte cell cultures were used as control 
cells. 
 
Arginase activity measurement 
After that the cultured cells reached confluence, lysate of 3 x 106 normal (n=8) or 3 x 
106 KC keratocytes (n=8) was prepared using 10 mM Tris/HCL buffer (pH 7.4) 
containing 0.4 % (w/v) Triton™ X-100 with additional 3 freeze and thaw cycles. 
Following centrifugation, the supernatant was used for the assay. The test was 
performed according to the manufacturer’s protocol. Shortly, arginase from samples 
catalyzes the conversion of arginin to urea and ornithine. The produced urea 
specifically reacts with the substrate to generate a colored product, proportional to the 
arginase activity. The absorbance was measured at 550 nm using an absorbance 
microplate reader (TECAN infinite 50, TECAN Deutschland GmbH, Crailsheim, 
Germany). The arginase activity of each sample was calculated using the absorbance 
of a standard solution.  
 
Protein measurement 
After taking the supernatant for hydroxyproline determination, the total protein 
concentration of each well was measured to calculate the amount of hydroxyproline 
per mg protein, as follows. Following detachment of the cells with 150 µl CelLytic™, 
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protein quantity was determined according to the method of Bradford, which is based 
on the formation of a complex between the dye, Brilliant blue G and proteins in 
solution. The absorbance was measured at 595 nm and the concentrations were 
quantified using bovine serum albumin (BSA) as standard. 
 
Urea concentration measurement in keratocytes 
Lysate of 5 x 106 normal (n=5) and KC keratocytes (KC) (n=5) was prepared using 10 
mM Tris/HCL buffer (pH 7.4) containing 0.4 % (w/v) Triton™ X-100 with additional 
3 freeze and thaw cycles. After centrifugation, the supernatant was used for the assay. 
The test was performed according to the manufacturer’s protocol: Urea concentration 
was determined by a coupled enzyme reaction, which results in a colorimetric product, 
proportional to the urea concentration. The optical density was measured at 550 nm 
using an absorbance microplate reader (TECAN infinite 50). The urea concentration 
of each sample was calculated using the optical density of a standard solution.  
 
Urea treatment of keratocyte cell cultures before hydroxyproline measurement 
Keratocytes were seeded in a 24-multiwell plate at a density of 8 x 103 cells/cm2 in 
culture medium of 1 ml per well. After a growth period of 48 h the culture medium 
was changed to culture medium containing urea concentrations of 0, 5.0 and 10.0 mM 
for 24 h at 37°C for 24 hours. The supernatant was stored at -80°C until 
hydroxyproline measurement. 
 
Hydroxyproline measurement 
Hydroxyproline measurement in the supernatant of urea treated keratocytes was 
performed by a colorimetric assay kit with linear detection ranges of 6 µg/ml - 400 
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µg/ml. The measured concentrations below the lower threshold of this range were 
considered as zero. The measurements were performed following the manufacturer’s 
protocol. First, supernatant of keratocytes was hydrolyzed with 10 N HCL at 120°C 
for 24 hours. Then, sample solutions were transferred to microcentrifuge tubes and 
were spun at 10,000 rpm for 3 minutes. Thereafter, the supernatant of the solution was 
pipetted into a 96 well-plate and was treated with chloramine-T and Ehrlich reagent 
(dimethylaminobenzaldehyde). Additional microplate wells were filled with known 
dilutions of hydroxyproline and were used to create a calibration curve. The optical 
density of each well was measured with an absorbance microplate reader at 550 nm 
(TECAN infinite 50). Hydroxyproline content in samples was then determined using 
regression analysis. In each well, the concentration of hydroxyproline was normalized 
to the cell protein concentration of the respective well.  
 
Keratocyte viability using different urea concentrations 
Cell viability was evaluated using the alamarBue® assay as follows: human 
keratocytes were seeded in 24-well cell culture plates at a density of 7.5 × 103 
cells/cm2. After a growth period of 24 h, the culture medium was changed to culture 
medium containing urea concentrations of 0, 0.5, 1.0, 5.0 and 10.0 mM at 37°C for 24 
h. Subsequently alamarBlue® solution was diluted with culture medium for a final 
concentration of 10% and 500 µl of this solution was added to each well. As a 
negative control, alamarBlue® solution was added to a well without cells. Absorbance 
was measured at 550 nm using a 96-well microplate reader (Tecan infinite F50). 
 
Keratocyte proliferation using different urea concentrations 
To detect the impact of urea on the proliferation rate of the keratocytes, the 
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proliferation was determined with the proliferation ELISA-BrdU kit, by the 
measurement of BrdU(5-bromo-2’deoxyuridine) incorporation in the newly 
synthesized cellular DNA. Keratocytes were seeded in a 96-multiwell plate at a 
density of 6 x 103 cells/cm2 in culture medium of 100 µl per well. After a growth 
period of 24 h, the culture medium was changed to culture medium containing urea at 
0, 0.5, 1.0, 5.0 and 10.0 mM at 37°C for 24 hours. The test was performed according 
to the manufacturer’s protocol. Briefly, BrdU was added to the keratocytes and 
incubated at 37°C for 4 h. After removing the culture medium, the cells were fixed 
with FixDenat, provided with the test kit, followed by the incubation with 
anti-BrdU-POD (peroxidase), which binds the incorporated DNA. After adding the 
substrate solution, the immune complex was detected using an absorbance microplate 
reader (Tecan Infinite 50). 
 
Statistical Analysis  
For statistical analysis the GraphPad Prism 2.01 was used. Data are represented as 
mean ± standard deviation (SD). Statistical analysis was performed using 
Wilcoxon-Mann-Whitney Test. P values below 0.05 were considered statistically 
significant.  
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RESULTS 
Arginase activity in KC-keratocytes was significantly decreased compared to normal 
keratocytes (p=0.003), as shown in Figure 2. In line with this finding the 
concentration of the arginase reaction product, urea was also significantly lower in 
cultured KC-keratocytes (5.36 ng/µl) than in normal keratocytes (8.89 ng/µl; p=0.008) 
(p=0.008) (Figure 3). The significantly lower hydroxyproline concentration in the 
KC-keratocyte cultures indicated impaired collagen synthesis compared to normal 
keratocytes (Figure 4), although treatment with 5.0 or 10.0 mM urea did not change 
significantly the viability of KC-keratocytes compared to controls (p>0.09) (data not 
shown). The difference in the hydroxyproline content of normal and KC-keratocytes 
decreased after 24-h urea exposure, but remained significant (p=0.02 and 0.03) 
(Figure 4). The treatment of normal keratocytes with different urea concentrations did 
not change cell proliferation significantly (p>0.09). However, proliferation of 
KC-keratocytes was significantly (p<0.05) increased by exposure to 0.5, 1.0 or 10.0 
mM urea, compared to keratoconus keratocyte cultures without urea treatment 
(Figure 5). 
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DISCUSSION 
Keratoconus is a severe disease of the cornea, resulting in thinning and conical shape 
[1]. There is an association between keratoconus and collagen disorders like 
Ehlers-Danlos syndrome and mitral valve prolapse [2]. However, the exact causes of 
keratoconus remain unknown.  
In patients with keratoconus, the tissue develops biomechanical instability, which 
results in conical shape. The production of collagen by corneal keratocytes is a major 
factor in biomechanical stability and shape of the cornea [15]. Impairment of collagen 
synthesis may be a possible reason for the development of keratoconus.  
Recent years literature on the role of arginase in the immune system increased 
enormously, as it has a crucial role in various aspects of inflammation such as 
inflammation triggered immune dysfunction, tumor immune escape, 
immunosuppression and immunopathology of infectious disease [16]. Arginase is a 
manganese metalloenzyme, which plays a major role in collagen synthesis. Arginase 
is responsible for the conversion of L-arginine to L-ornithine and urea. L-ornithine is 
further converted to proline. Proline is partially hydroxylated into hydroxyproline that 
stabilizes the triple helical subunits of collagen [17]. Adequate amount and activity of 
the enzyme arginase is essential for proline supply in keratocytes for collagen 
synthesis (Figure 1).  
In our current study, we found impaired arginase activity in human KC keratocytes, 
compared to normal keratocytes. The most conspicuous finding of our study is that 
arginase activity, urea concentration and hydroxyproline synthesis are reduced in 
keratoconus keratocytes. Decreased arginase activity could be proven through two 
independent methods in our study. First, we directly measured decreased arginase 
activity in KC keratocytes compared to normal keratocytes. Second, as an indirect 
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measurement, the level of urea, as one product of the enzyme arginase was also 
decreased. Decreased urea concentration in aqueous humour of KC patients could also 
be verified in our previous work, compared to controls [12]. These previous in vivo 
measurement data further support results of our present in vitro experiments.  
With decreased arginase activity in KC keratocytes we have also found decreased 
hydroxyproline synthesis in KC keratocytes, compared to normal controls. It is to note, 
that the hydroxyproline concentration in keratocyte cultures is decreased, despite the 
supplemented L-arginine and L-proline in the culture medium. This supports the 
conclusion that the exogenous proline is insufficient for cells with active collagen 
synthesis that require excessive amounts of this amino acid. The arginase activity of 
keratocytes may be the limiting step in the synthesis of collagen.  
All of the above data (decreased arginase activity, urea concentration and 
hydroxyproline synthesis) suggest an arginase-dependent impairment of collagen 
synthesis in keratoconus keratocytes. Whether arginase activity is impaired or the 
level of arginase expression is reduced through inherited or acquired factors remains 
to be further clarified. 
Another novel aspect of our work was the effect of urea on the viability, proliferation 
and hydroxyproline synthesis of normal and KC keratocytes. We found that urea 
treatment stimulated the proliferation of KC-keratocytes, but not of normal 
keratocytes without any changes in the viability of either cell type. Interestingly, 
Moeslinger et al. also found a proliferation promoting effect of urea on macrophages 
[18].  
Keratocytes show a downregulated MYC-gene (MYC, proto-oncogene protein), which 
is involved in cell cycle regulation [19]. MYC is a transcription factor that can bind 
the DNA and activate several regulation processes. The activation of MYC can 
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promote cell growth and proliferation [20]. Urea may be involved in cell signaling to 
activate the MYC-gene for cell proliferation [19] or increasing urea concentrations 
slow down arginase activity and through the accumulation of arginine enhance cell 
proliferation [11]. These pathways have to be further analyzed in keratoconus patients.  
A further reason for the decreased amount of hydroxyproline may be the reduced 
concentration of L-arginine through the competing nitric oxide (NO) pathway (Figure 
1). If the collagen production is impaired, NO pathway may also show altered 
processes. In addition, it is suggested, that the development of keratoconus is also 
associated with increased levels of reactive oxygen species - these may also be 
involved in alterations of keratoconus corneas [21]. Therefore, further experiments 
concerning NO production via nitric oxide synthase have to be performed using 
keratoconus corneas. 
In summary, arginase activity, urea concentration and hydroxyproline synthesis are 
reduced in keratoconus keratocytes. Urea treatment of keratoconus keratocytes does 
not change viability, but stimulate proliferation of these cells. The metabolic 
reprogramming of keratoconus keratocytes and its impact on development of a 
clinically detectable keratoconus disease has to be further analyzed. 
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Figure 1. Arginase, as a cytoplasmic enzyme catalyzes the conversion of L-arginine 
to L-ornithine and urea. Ornithine will be further transformed by the sequential action 
of ornithine aminotransferase (OAT) and pyrroline-5-carboxylate reductase (P5CR) 
to proline. Following the translation of protocollagen, some of its proline residues are 
hydroxylated to hydroxyproline by prolyl-4-hydroxylase. Ornithine is also converted 
by the enzyme ornithine decarboxylase (ODC) to polyamines. The competing enzyme 
for the substrate L-arginine is nitric-oxide synthase (NO-Synthase), which catalyzes 
the reaction to nitric oxide.  
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Figure 2. Arginase activity in normal and keratoconus (KC) keratocytes. Significant 
difference is indicated. 
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Figure 3. Urea concentration in normal and keratoconus (KC) keratocytes. Significant 
difference is indicated. 
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Figure 4. Hydroxyproline synthesis in cultures of normal and keratoconus (KC) 
keratocytes 24 hours after urea treatment. Hydroxyproline synthesis of keratocytes 
was significantly less in keratoconus cultures compared to normal keratocytes adding 
0, 5.0 or 10.0 mM concentrations of urea to the cultures (p= 0.02, 0.02 and 0.03). 
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Figure 5. Proliferation rate of normal and keratoconus (KC) keratocytes. 
Incorporation of BrdU(5-bromo-2’deoxyuridine) in the newly synthesized cellular 
DNA was measured after 24-h exposure to urea at the indicated concentrations in the 
culture medium. The absorbance of untreated keratocytes was set to 100%, significant 
differences are indicated. 
The treatment of normal keratocytes with different urea concentrations did not change 
keratocyte proliferation significantly compared to control cells (p>0.09). However, 
proliferation of KC keratocytes was significantly increased using 0.5, 1.0 or 10.0 mM 
concentrations of urea (p= 0.04; 0.04; 0.04), compared to KC keratocyte cultures 
without urea treatment.  
 
